| Literature DB >> 32424443 |
Nicoleta Spinu1, Mark T D Cronin1, Steven J Enoch1, Judith C Madden1, Andrew P Worth2.
Abstract
The quantitative adverse outcome pathway (qAOP) concept is gaining interest due to its potential regulatory applications in chemical risk assessment. Even though an increasing number of qAOP models are being proposed as computational predictive tools, there is no framework to guide their development and assessment. As such, the objectives of this review were to: (i) analyse the definitions of qAOPs published in the scientific literature, (ii) define a set of common features of existing qAOP models derived from the published definitions, and (iii) identify and assess the existing published qAOP models and associated software tools. As a result, five probabilistic qAOPs and ten mechanistic qAOPs were evaluated against the common features. The review offers an overview of how the qAOP concept has advanced and how it can aid toxicity assessment in the future. Further efforts are required to achieve validation, harmonisation and regulatory acceptance of qAOP models.Entities:
Keywords: Bayesian network; Computational approach; Key event relationship; Predictive toxicology; Quantitative adverse outcome pathway (qAOP); Response-response relationship
Mesh:
Year: 2020 PMID: 32424443 PMCID: PMC7261727 DOI: 10.1007/s00204-020-02774-7
Source DB: PubMed Journal: Arch Toxicol ISSN: 0340-5761 Impact factor: 5.153
Common features of qAOP models in the scientific literature
| Common feature | Description | Criteriaa |
|---|---|---|
| Problem formulation | • A qAOP should answer a well-defined question relevant to the AO of interest • The purpose of the model dictates how much mechanistic understanding is required, and the way a qAOP should be developed, validated and used | • Question addressed and/or purpose of modelling • AO studied |
| Mechanistic knowledge and associated data | • The OECD AOP-Wiki can support the development of a qAOP model to predict an endpoint of interest. Empirical data for model parametrisation, fitting and/or testing can be obtained from the description of KERs published in the AOP-Wiki • Whilst for quantification it is recommended to start with linear AOPs, it should not impede quantification of networks or highly connected KEs/KERs within an AOP network • A qAOP model relies heavily on data: not only bioactivity of a compound/mixtures but also, measurements of effects at relevant doses/concentrations and appropriate time scales including physicochemical properties and molecular descriptors. Data may come from a range of in vivo and in vitro studies specifically designed to test an AOP as a hypothesis and/or retrieved from a variety of sources to assist with this process • Both adjacent and non-adjacent KEs paired as upstream–downstream in a KER should be quantified even though each of them impacts differently on the modelling process, e.g. in the context of Bayesian network modelling. Adjacency refers to whether there are other KEs positioned in between of the linear construction of an AOP or not • Different biological level of organisations should be quantified if this is relevant to the AO of interest and available data allowed | • Presence of the AOP in the OECD AOP-Wiki • Type of AOP: linear or network • Type of chemical model applied to (single chemical(s)/mixtures) • Type of data: in vivo, in vitro, in silico and/or other variables • Dose/concentration–responses • (D/C–R) and time–responses (T–R) • Adjacency of KERs: adjacency and non-adjacency • Biological levels: cellular, tissue, organ, organism, population |
| Quantitative approach | • The modelling approaches can vary from being probabilistic to deterministic • The mathematical expression can take various forms including linear regressions and ordinary differential equations resulting in different graphical shapes, e.g. linear, sigmoidal, Gaussian-type plots | • Type of quantitative approach |
| Regulatory applicability | • A qAOP model should imply various applications to regulatory decision-making and acceptance | • Human health/ecological risk assessment |
| Additional considerations | • These considerations can influence the regulatory approval, reduce the uncertainties, and extend the applicability domain of the predictions of a qAOP model • It is not mandatory that the test methods used (models and measured endpoints) are adopted/validated following national/international guidelines. However, they should be performed in a quality-controlled environment where relevance of the model is proved based on scientific rationale and reproducibility of data • Even though none of the definitions identified referred to uncertainty and sensitivity analysis, this aspect should be considered as well for its value in validating the predictions of a qAOP model while giving confidence in its further applications | • Cross species extrapolation • Modulating factors • Positive/negative feedback loops • Compensatory mechanisms • Test method adopted/validated • Kinetics • Exposure assessment • Uncertainty evaluation • Sensitivity analysis • Availability: open access or not |
aThe criteria were used to characterise available qAOP models
Characterisation of five probabilistic models that use the Bayesian network approach and an AOP construct
| Model purpose | Adverse outcome | Mechanistic knowledge and associated data | Quantitative approach | Regulatory applicability | References | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OECD AOP-Wiki a | Type of AOPd | Type of chemical model applied to | Data type | Adjacent KERs | Biological level(s) | D/C–Re | T–Rf | |||||
| The risk posed by pesticides and environmental stressors to population size of Chinook salmon | Alteration of population dynamics | Nob | AOPN | Mixtures | In vitro experimental data, literature data, AOP construction, environmental factors, population characteristics | √ | Molecular, cellular, organ, organism, population | √ | √ | Bayesian Network-Relative Risk type of model | Ecological risk assessment | Chu ( |
| Effects on reproduction of | Reduced number of fronds | AOP ID 245 | LAOP | Single chemical | In vitro experimental data, AOP construction | √ | Molecular, cellular, organism | √ | – | Bayesian network type of model (discrete states as three intervals) | Ecological risk assessment | Moe et al. ( |
| Toxicity of silver nanoparticles, linking MIE to the AO | Reproduction failure | AOP ID 207 | LAOP | Nanoparticles | In vitro experimental data, literature data, AOP construction | √ | Molecular, cellular, organ, organism | √ | √ | Bayesian network type of model (discrete states as yes/no, and decrease/stable/increase), Boostrapping | Ecological risk assessment | Jeong et al. ( |
| Occurrence of steatosis under different chemical exposures | Hepatic steatosis | Noc | AOPN | Mixtures | Expert judgment, literature data, AOP construction | √ | Molecular, cellular, tissue, organ | √ | – | Bayesian network type of model (discrete states as active or inactive) | Human health risk assessment | Burgoon et al. ( |
| Comparison between probabilistic and mechanistic approaches | Nephron attrition leading to chronic kidney disease | AOP ID 284 | LAOP | Single chemical | In vitro experimental data on human RPTEC/TERT1 cells, AOP construction | √ | Molecular, cellular, tissue, organ | √ | √ | Dynamic Bayesian network type of model | Human health risk assessment | Zgheib et al. ( |
aNumbers represent the indices (XXX) of the AOP in the AOP-Wiki available at https://aopwiki.org/aops/XXX
bModel follows an AOP structure, the MIE (ID 12) can be found in the AOP-Wiki, however the AOP itself is not yet published
cModel is included in the AOPXplorer tool (https://apps.cytoscape.org/apps/aopxplorer) as it follows the structure of an AOP network
dLinear AOP (LAOP), AOP Network (AOPN)
eDose/Concentration–Response (D/C–R)
fTime–Response (T–R) describing the time-course behaviour
gModel represents a combination of both probabilistic and mechanistic approaches
Characterisation of ten mechanistic qAOPs
| Model purpose | Adverse outcome | Mechanistic knowledge and associated data | Quantitative approach | Regulatory applicability | References | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OECD AOP-Wikia | Type of AOPb | Type of chemical model applied to | Data type | Adjacent KERs | Biological level(s) | D/C–Rc | T–Rd | |||||
| Association of MIE to AO at higher level of biological organisations | Increased frequency of spontaneous tail contractions | No | LAOP | Single chemical | In vivo experimental data | √ | Molecular, tissue, organ | √ | √ | Statistical analysis | Ecological risk assessment | Yozzo et al. ( |
| Mechanism of CuO engineered nanoparticles toxicity | Mortality | No | LAOP | Nanoparticles | In vitro experimental data | √ | Molecular, cellular, organ, organism | √ | √ | Linear regression, one-compartment toxicokinetic model | Ecological risk assessment | Muller et al. ( |
| Development of a qAOP network | Egg production | No | AOPN | Single chemical | In vitro and in vivo experimental data | √ | Molecular, cellular, tissue, organ, individual | √ | √ | Statistical analysis | Ecological risk assessment | Margiotta-Casaluci et al. ( |
| Development of a qAOP and potential applications | Population declining trajectory (reproductive dysfunction) | AOP ID 25 | LAOP | Single chemical | Empirical data | √ | Molecular, cellular, tissue, organ, individual, population | √ | √ | A mechanistic model, a compartment model, a statistical model, a density-dependent population matrix model | Ecological risk assessment | Conolly et al. ( |
| Development of a qAOP on developmental neurotoxicity | Brain malformation | AOP ID 42 | LAOP | Single chemical | In vivo experimental data | √f | Molecular, cellular, tissue, organ | √ | √ | Mathematical equations (exponential regression) | Human risk assessment | Hassan et al. ( |
| Development of a cross-species qAOP | Mortality increase, population declining trajectory | AOP ID 150 | LAOP | Mixtures | In vitro experimental data on COS-7 cells | √f | Molecular, organism, population | √ | – | Linear regression, statistical analysis | Ecological risk assessment | Doering et al. ( |
| Simulation of the mechanism of toxicity | Abnormalities at facial primordia branchial arches | No | LAOP | Single chemicals | In vitro experimental data, in vivo and in silico data | √ | Molecular, cellular, tissue, organ | √ | √ | Multistage dose–response model, Bayesian analysis | Ecological risk assessment | Battistoni et al. ( |
| Define the taxonomic domain of applicability of an existing qAOP | Decreased fecundity | AOP ID 25 | LAOP | Single chemical | In vivo experimental data | √ | Cellular, tissue, organ, individual | √ | √ | Regression, statistical analysis | Ecological risk assessment | Doering et al. ( |
| Quantification of qKERs with available data in a modular manner | Decrease in population; Impairment of memory and learning | AOPs IDs 25 and 48 | LAOP | Single chemicals | Empirical data | √f | √ | – | Linear regression (response-response function) | Screening or prioritisation | Foran et al. ( | |
| Comparison between probabilistic and mechanistic approaches | Nephron attrition leading to chronic kidney disease | AOP ID 284 | LAOP | Single chemicals | In vitro experimental data on human RPTEC/TERT1 cells, AOP construction | √ | Molecular, cellular, tissue, organ | √ | √ | Empirical dose–response model, systems biology model | Human health risk assessment | Zgheib et al. ( |
aNumbers represent the indices (XXX) of the AOP in the AOP-Wiki available at https://aopwiki.org/aops/XXX
bLinear AOP (LAOP), AOP Network (AOPN)
cDose/Concentration–Response (D/C–R)
dTime–Response (T–R) describing the time-course behaviour
eModel represents a combination of both probabilistic and mechanistic approaches
fNon-adjacent KERs were modelled as well
Characterisation of the available qAOP models based on the additional considerations listed in Table 1
| References | Cross species extrapolation | Modulating factors | Feedback loops | Compensatory mechanisms | Test method adopted/validated | Kinetics | Exposure assessment | Uncertainty evaluation | Sensitivity analysis | Publicly available |
|---|---|---|---|---|---|---|---|---|---|---|
| Chu ( | – | √ | – | – | – | – | √ | √ | √ | √ |
| Moe et al. ( | – | –– | – | – | √a | – | – | √ | √ | √ |
| Jeong et al. ( | – | – | – | – | – | √ | – | – | √ | √ |
| Burgoon et al. ( | – | – | – | – | – | – | – | – | √ | √ |
| Zgheib et al. ( | – | – | – | – | – | – | – | √ | √ | √ |
| Yozzo et al. ( | – | – | – | – | – | – | – | – | – | – |
| Muller et al. ( | – | – | – | – | – | √ | – | – | – | √ |
| Margiotta-Casaluci et al. ( | – | – | √ | – | – | √ | – | – | √ | – |
| Conolly et al. ( | – | – | √ | √ | – | √ | – | √ | – | – |
| Hassan et al. ( | – | – | √ | √ | – | √ | √ | √ | – | √ |
| Doering et al. ( | √ | – | – | – | – | – | – | √ | – | √ |
| Battistoni et al. ( | – | √ | √ | – | – | – | √ | √ | – | – |
| Doering et al. ( | √ | – | – | – | – | √ | – | √ | √ | – |
| Foran et al. ( | – | – | – | – | – | – | – | – | – | – |
| Zgheib et al. ( | – | – | – | – | – | – | – | √ | √ | √ |
aThe in vitro measurements were conducted on a plant recognised in the OECD test guidelines for toxicity testing of the endpoint
Fig. 1Conceptual representation of available types of qAOP models. Qualitative AOPs have an informative role for prioritisation and computational modelling of the AO of interest and can additionally be quantified by a weight-of-evidence. A common approach to probabilistic modelling relies on the use of Bayes theorem as described below. Mechanistic qAOP models utilise mathematical functions including linear regressions